Connor, Clark & Lunn Investment Management Ltd. Poseida Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 153,058 shares of PSTX stock, worth $1.45 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
153,058
Previous 359,197
57.39%
Holding current value
$1.45 Million
Previous $1.03 Million
43.04%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding PSTX
# of Institutions
118Shares Held
40.7MCall Options Held
135KPut Options Held
427K-
Pentwater Capital Management LP Naples, FL8.63MShares$81.9 Million0.95% of portfolio
-
Nomura Holdings Inc Tokyo, M05.12MShares$48.6 Million0.07% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$46.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.83MShares$36.4 Million0.0% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.02MShares$19.2 Million1.2% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $815M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...